SCIENTECH (02291.HK): Interim Revenue Down 5.9% to RMB 310.1 Million, Net Profit Down 19.5%

NewTimeSpace News: On 22 September 2026, LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (stock code: 02291) published its 2026 interim report. For the six months ended 30 June 2026, the Group's revenue decreased by 5.9% from RMB 329.7 million for the six months ended 30 June 2025 to RMB 310.1 million, and gross profit decreased by 10.5% from RMB 284.3 million to RMB 254.5 million.

Research and development expenses decreased by 22.9% from RMB 25.4 million for the six months ended 30 June 2025 to RMB 19.5 million, and net profit attributable to shareholders of the parent company decreased by 19.5% from RMB 182.0 million to RMB 146.5 million. The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2026.

The Group focuses on the research and development, production and commercialisation of interventional medical devices for structural heart disease and pan-cardiovascular diseases. It has established a profound technological accumulation and market foundation in the field of traditional metal occluders, and has applied biodegradable materials to interventional devices for structural heart disease, being one of the first enterprises globally to commercialise biodegradable occluders, with many products being the world's first of their kind approved for marketing. As at the date of the report, the Group owned a total of 32 marketed products, with a further 3 products in the registration review or preparation stage and 27 products at different research and development stages.

As an event after the reporting period, on 21 August 2026 the Company entered into an equity transfer agreement with Lepu Medical to acquire 54.2384% of the equity interest in Shanghai Minwei Biotechnology Co., Ltd. held by Lepu Medical for a cash consideration of RMB 1,088,387,980; the acquisition constituted a major transaction under Chapter 14 and a connected transaction under Chapter 14A of the Listing Rules.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.